Predictive and on-treatment monitoring biomarkers in advanced melanoma: moving toward personalized medicine
Melanoma incidence is increasing globally, with 351,880 cases reported in 2015 [1]. In the United States alone, an estimated 91,270 new cases and 9320 deaths are predicted in 2017 [2].The treatment of unresectable or metastatic melanoma has been transformed by the introduction of novel molecularly targeted and immune therapies [3 –6]. The discovery of driver oncogenes has facilitated the clinical development of targeted therapies, ushering in the era of personalized medicine. In melanoma, this has been exemplified by the success of agents targeting BRAF and downstream MEK proteins in patients with activating BRAF mutations [7–11].
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Ahmad Tarhini, Ragini R. Kudchadkar Tags: Anti-Tumour Treatment Source Type: research